Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Canadian Cancer Society awards London scientists new funds for innovative research

Three London scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Myriad Genetics, Inc. today reported financial results for the third fiscal quarter and the nine-month period ended March 31, 2010.

5 May 2010

Theragenics reports highest quarterly consolidated revenue of $20.3 million

Theragenics Corporation®, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2010.

4 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

GTx, Inc. today reported financial results for the first quarter of 2010. The net income for the first quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009. Net income for the current period included the recognition of approximately $54.9 million in collaboration revenue due to the termination of our license and collaboration agreement with Merck & Co., Inc in March 2010.

4 May 2010

New study finds stereotypies in more than 60% of orphaned or abandoned children

Stereotypies -- repetitive behaviors such as rocking, flapping, spinning objects and head-banging – are commonly seen in people with autism or mental retardation. They can also be acquired by children exposed to severe neglect and deprivation, along with declines in IQ, mental health and language.

4 May 2010

Study comparing enteroscopy technologies finds SE quicker than DBE for examining small intestine

Spirus Medical, Inc., a leading developer of diagnostic and therapeutic advancement systems for gastroenterology, announced at Digestive Disease Week 2010 that results from the first-ever prospective study comparing enteroscopy technologies show spiral enteroscopy (SE) to be more than three times faster, on average, than double-balloon enteroscopy (DBE) in examining the small intestine.

4 May 2010

CA-BSI can be reduced in children through quality improvement efforts: Study

Bloodstream infections associated with catheters can be significantly reduced through quality improvement efforts, possibly leading to better health outcomes and lives saved, decreased stays at the hospital and related costs, according to a new study.

4 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Spectros, Philips Electronics enter patent sale agreement covering multispectral pulse oximetry technology

Spectros announced today that it entered into a patent sale agreement with Koninklijke Philips Electronics N.V. ( PHG). Under this agreement, Philips purchased a patent related to technology for multispectral pulse oximetry, an approach first developed and patented by Spectros.

3 May 2010

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.

3 May 2010

Research roundup: Managing nursing home patients, streamlining medical billing, financial disclosures

Saving Billions Of Dollars--And Physicians' Time--By Streamlining Billing Practices - "The U.S. system of billing third parties for health care services is complex, expensive, and inefficient," write the authors, who analyzed Massachusetts General Physicians Organization staffing and cost data in fiscal year 2006.

3 May 2010

FDA oks 'vaccine' to treat prostate cancer

Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.

3 May 2010

Ipsen's first-quarter 2010 drug sales up 6.2%

Ipsen reported today its sales for the first quarter 2010.

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Endo Pharmaceuticals today reported financial results for the first quarter 2010.

30 Apr 2010

FDA grants marketing clearance for Immucor's NEO automated blood bank instrument

Immucor, Inc., a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that its fourth generation automated instrument, NEO™, has been cleared for marketing in the U.S. by the Food and Drug Administration ("FDA"). NEO is a fully automated blood bank instrument designed to meet the needs of high volume laboratories.

30 Apr 2010

Researchers use healthy person's complete genome sequence to predict risk for dozens of diseases

For the first time, researchers have used a healthy person's complete genome sequence to predict his risk for dozens of diseases and how he will respond to several common medications. The risk analysis, from the Stanford University School of Medicine, also incorporates more-traditional information such as a patient's age and gender and other clinical measurements.

30 Apr 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Canadian Cancer Society awards London scientists new funds for innovative research

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Theragenics reports highest quarterly consolidated revenue of $20.3 million

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

New study finds stereotypies in more than 60% of orphaned or abandoned children

Study comparing enteroscopy technologies finds SE quicker than DBE for examining small intestine

CA-BSI can be reduced in children through quality improvement efforts: Study

FDA issues advisory on prostate cancer drugs

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Spectros, Philips Electronics enter patent sale agreement covering multispectral pulse oximetry technology

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Research roundup: Managing nursing home patients, streamlining medical billing, financial disclosures

FDA oks 'vaccine' to treat prostate cancer

Ipsen's first-quarter 2010 drug sales up 6.2%

VIMOVO delayed-release tablets receive FDA approval

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

FDA grants marketing clearance for Immucor's NEO automated blood bank instrument

Researchers use healthy person's complete genome sequence to predict risk for dozens of diseases

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in